Clinical Trial Update: Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

Investigator-initiated trial evaluating durvalumab and guadecitabine in advanced kidney cancer (Phase 1/2; status: active not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Kidney Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Guadecitabine (guadecitabine)

Snippet

Sponsor: Ajjai Alva, MD | Conditions: Advanced Kidney Cancer, Kidney Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING